SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
From the Blogosphere
After-Hours Movers 1/6: La Jolla (LJPC), NetScout (NTCT), Interwoven (IWOV) Higher; SMSC (SMSC), IXYS (IXYS), F5 (FFIV), Global Payments (GPN), Alcoa (AA) Lower
|
La Jolla Pharmaceutical (Nasdaq: LJPC) 166% HIGHER; BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and La Jolla have entered into an agreement to develop and commercialize Riquent, La Jolla's investigational drug for lupus nephritis, in the United States, Europe and all other territories of the world, excluding the Asia Pacific region. Under the terms of the agreement, BioMarin will receive a co-exclusive license to develop and commercialize Riquent and La Jolla could receive up to $289 million in cash through milestones and equity purchases by BioMarin. Specific payments include: $15 million ...
|
After-Hours Movers 1/6: La Jolla (LJPC), NetScout (NTCT), Interwoven (IWOV) Higher; SMSC (SMSC), IXYS (IXYS), F5 (FFIV), Global Payments (GPN), Alcoa (AA) Lower
|
La Jolla Pharmaceutical (Nasdaq: LJPC) 166% HIGHER; BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and La Jolla have entered into an agreement to develop and commercialize Riquent, La Jolla's investigational drug for lupus nephritis, in the United States, Europe and all other territories of the world, excluding the Asia Pacific region. Under the terms of the agreement, BioMarin will receive a co-exclusive license to develop and commercialize Riquent and La Jolla could receive up to $289 million in cash through milestones and equity purchases by BioMarin. Specific payments include: $15 million ...
|
After-Hours Movers 1/6: La Jolla (LJPC), NetScout (NTCT), Interwoven (IWOV) Higher; SMSC (SMSC), IXYS (IXYS), F5 (FFIV), Global Payments (GPN), Alcoa (AA) Lower
|
La Jolla Pharmaceutical (Nasdaq: LJPC) 166% HIGHER; BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and La Jolla have entered into an agreement to develop and commercialize Riquent, La Jolla's investigational drug for lupus nephritis, in the United States, Europe and all other territories of the world, excluding the Asia Pacific region. Under the terms of the agreement, BioMarin will receive a co-exclusive license to develop and commercialize Riquent and La Jolla could receive up to $289 million in cash through milestones and equity purchases by BioMarin. Specific payments include: $15 million ...
|
After-Hours Movers 1/6: La Jolla (LJPC), NetScout (NTCT), Interwoven (IWOV) Higher; SMSC (SMSC), IXYS (IXYS), F5 (FFIV), Global Payments (GPN), Alcoa (AA) Lower
|
La Jolla Pharmaceutical (Nasdaq: LJPC) 166% HIGHER; BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and La Jolla have entered into an agreement to develop and commercialize Riquent, La Jolla's investigational drug for lupus nephritis, in the United States, Europe and all other territories of the world, excluding the Asia Pacific region. Under the terms of the agreement, BioMarin will receive a co-exclusive license to develop and commercialize Riquent and La Jolla could receive up to $289 million in cash through milestones and equity purchases by BioMarin. Specific payments include: $15 million ...
|
52 Week Low's 2/13
|
|
|
TONE Tierone Corp
STXX South Texas Oil Co
RNGY Renegy Holdings Inc
LNCE Lance Inc
LNCB Lincoln Bancorp Ind
LJPC La Jolla Pharmaceutic ...
JKAU Jk Acquisition Corp
DFG Delphi Finl Group Inc
DAKT Daktronics Inc
CPI Capital Properties, Inc
COO The Cooper Companies, Inc
BLD Baldwin Technology Co ...
BELM Bell Microproducts Inc
BBEP Breitburn Energy Part ...
BASI Bioanalytical Sys Inc
Disclosure ("none" means no position):
↑ Grab this Headline Animator
Visit the ValuePlays Bookstore for Great Investing Books
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on LJPC |
Visit streetinsider.com
More Resources
|
About La Jolla Pharmaceutical Company
- Answers.com
